ISSN:
1432-1440
Keywords:
Kaposi's sarcoma
;
Interferon-alpha
;
Zidovudine
;
Combination therapy
;
HIV antigenemia
;
Bone marrow suppression
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary A combination of oral zidovudine (250 mg twice daily) and subcutaneous interferon-alpha (10×106 units daily) was evaluated for clinical, antiretroviral, and immunological efficacy and for side effects in 17 patients with AIDS-related Kaposi's sarcoma. Fifteen patients were evaluable. During the study period of 12 weeks, tumor responses were complete in two patients and partial in two patients (27% major response rate). Minimal responses were seen in two patients (40% overall response rate). An anti-HIV effect (reduction of serum p24 antigen by 70% or more) was observed in seven of ten evaluable patients who were initially antigenemic. CD4 lymphocyte counts remained unchanged. In six patients who had either a tumor response or a marked decline of HIV antigenemia, the treatment was continued between 12 and 59 weeks beyond the study period. Two of four patients with tumor regression at 12 weeks had an additional tumor response in this period despite prior dose reduction of interferon due to toxicity. Late progression of KS was eventually observed in four of six patients on prolonged treatment. The responsiveness of Kaposi's sarcoma seen in this study in patients with low CD4 counts and prior constitutional symptoms (fever, weight loss) was unexpected and needs further confirmation by larger patient groups. Dose-limiting toxicities were bone marrow depression (severe anemia in four and neutropenia with anemia in two patients), subjective adverse experiences (fever, fatigue, myalgia; four patients) and both (two patients). Adjustment of the interferon dose improved the subjective as well as the hematologic tolerance to the combined treatment. Thus, the combination of zidovudine and interferon-alpha can be considered as a possible treatment of AIDS-related Kaposi's sarcoma. However, its use may be limited by toxicity.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02115785
Permalink
